31.26
-0.38 (-1.20%)
| Previous Close | 31.64 |
| Open | 31.17 |
| Volume | 471,305 |
| Avg. Volume (3M) | 627,255 |
| Market Cap | 1,557,057,536 |
| Price / Earnings (Forward) | 1.43 |
| Price / Sales | 2.67 |
| Price / Book | 3.02 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2026 |
| Profit Margin | -7.95% |
| Operating Margin (TTM) | -4.82% |
| Diluted EPS (TTM) | -0.810 |
| Quarterly Revenue Growth (YOY) | 13.60% |
| Total Debt/Equity (MRQ) | 17.03% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | 22.19 M |
| Levered Free Cash Flow (TTM) | -10.42 M |
| Return on Assets (TTM) | -3.70% |
| Return on Equity (TTM) | -8.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | AtriCure, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | 0.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.90 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 3.37% |
| % Held by Institutions | 103.60% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (UBS, 75.94%) | Buy |
| Median | 52.50 (67.95%) | |
| Low | 45.00 (Needham, 43.95%) | Buy |
| Average | 51.17 (63.69%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 33.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 18 Feb 2026 | 54.00 (72.74%) | Buy | 32.26 |
| Canaccord Genuity | 18 Feb 2026 | 53.00 (69.55%) | Buy | 32.26 |
| Citizens | 18 Feb 2026 | 52.00 (66.35%) | Buy | 32.26 |
| UBS | 18 Feb 2026 | 55.00 (75.94%) | Buy | 32.26 |
| Needham | 12 Feb 2026 | 45.00 (43.95%) | Buy | 31.80 |
| JP Morgan | 16 Dec 2025 | 48.00 (53.55%) | Buy | 41.08 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CARREL MICHAEL H | - | 30.02 | -6,000 | -180,120 |
| WHITE ROBERT S. | - | - | 0 | 0 |
| Aggregate Net Quantity | -6,000 | |||
| Aggregate Net Value ($) | -180,120 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 30.02 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WHITE ROBERT S. | Director | 10 Mar 2026 | Option execute | 10,000 | - | - |
| CARREL MICHAEL H | Officer | 06 Mar 2026 | Disposed (-) | 6,000 | 30.02 | 180,120 |
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results |
| 12 Jan 2026 | Announcement | AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 |
| 17 Dec 2025 | Announcement | AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |